{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:55:39Z","timestamp":1781805339538,"version":"3.54.5"},"reference-count":62,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>Chronic kidney disease (CKD) is a progressive condition that affects &amp;gt;800 million people worldwide and remains underdiagnosed, especially in its early stages. Diabetes and hypertension are leading drivers of CKD, largely through hyperglycemia- and pressure-mediated kidney damage. The estimated glomerular filtration rate (eGFR) is a standard measure of kidney function, and clinicians increasingly track its decline (the eGFR slope) to catch early warning signs and guide treatment decisions. Key clinical trials, including CREDENCE, DAPA-CKD, EMPA-KIDNEY, FIDELIO-DKD, FIGARO-DKD, and FLOW, have demonstrated how newer classes of medications can help when added to baseline therapy with renin-angiotensin system blockers. These therapies include sodium\u2013glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists (finerenone), and glucagon-like peptide 1 receptor agonists. By targeting inflammation, hyperfiltration, oxidative stress, and metabolic imbalances, these medications significantly slow eGFR decline and reduce the risk of complications, such as cardiovascular events. Lifestyle interventions, including blood pressure, glycemic, and lipid control, and regular monitoring of eGFR and urinary albumin-to-creatinine ratio are essential components of care. Mounting evidence supports a multitargeted approach, where combination therapy addresses the diverse pathways involved in CKD progression. Regular eGFR and albuminuria assessments are critical for identifying patients at higher risk and monitoring their response to interventions.<\/jats:p>","DOI":"10.2337\/doc25-0017","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T19:02:09Z","timestamp":1775674929000},"page":"278-287","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["Estimated Glomerular Filtration Rate Slope, Chronic Kidney Disease Progression, and Pillars of Care in Patients With Diabetic Kidney Disease"],"prefix":"10.2337","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5871-1265","authenticated-orcid":false,"given":"Pamela R.","family":"Kushner","sequence":"first","affiliation":[{"name":"Family Medicine, University of California 1 , Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3868-9969","authenticated-orcid":false,"given":"Christian W.","family":"Mende","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California 2 , San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2026061813271410400_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"2026061813271410400_B2","first-page":"100341","article-title":"Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)","volume":"36","author":"Ali","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"2026061813271410400_B3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2217\/cpr.14.46","article-title":"Chronic kidney disease in the elderly: evaluation and management","volume":"11","author":"Mallappallil","year":"2014","journal-title":"Clin Pract (Lond)"},{"key":"2026061813271410400_B4","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/01.ASN.0000070147.10399.9E","article-title":"Risk factors for progressive chronic kidney disease","volume":"14","author":"McClellan","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2026061813271410400_B5","first-page":"7S","article-title":"Diabetes mellitus and hypertension: key risk factors for kidney disease","volume":"94","author":"Lea","year":"2002","journal-title":"J Natl Med Assoc"},{"key":"2026061813271410400_B6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2337\/diacare.23.1.51","article-title":"Trends in persistent proteinuria in adult-onset diabetes: a population-based study","volume":"23","author":"Larson","year":"2000","journal-title":"Diabetes Care"},{"key":"2026061813271410400_B7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/MNH.0b013e32835012ab","article-title":"APOL1 and kidney disease","volume":"21","author":"Pollak","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026061813271410400_B8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/1470320311430989","article-title":"Gene polymorphisms of angiotensin-converting enzyme and angiotensin II type 1 receptor among chronic kidney disease patients in a Chinese population","volume":"13","author":"Su","year":"2012","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2026061813271410400_B9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10157-005-0341-3","article-title":"Factors influencing the development of end-stage renal disease","volume":"9","author":"Iseki","year":"2005","journal-title":"Clin Exp Nephrol"},{"key":"2026061813271410400_B10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1681\/ASN.2007020252","article-title":"Low birth weight increases risk for end-stage renal disease","volume":"19","author":"Vikse","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2026061813271410400_B11","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1681\/ASN.2005060638","article-title":"Obesity and risk for chronic renal failure","volume":"17","author":"Ejerblad","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026061813271410400_B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nephro.2012.07.361","article-title":"Socio-economic impact in CKD","volume":"9","author":"Plantinga","year":"2013","journal-title":"Nephrol Ther"},{"key":"2026061813271410400_B13","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1093\/ndt\/gfi022","article-title":"Effects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus","volume":"20","author":"Orth","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"2026061813271410400_B14","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJM199412223312502","article-title":"Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs","volume":"331","author":"Perneger","year":"1994","journal-title":"N Engl J Med"},{"key":"2026061813271410400_B15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00467-010-1653-4","article-title":"Acute kidney injury in childhood: should we be worried about progression to CKD?","volume":"26","author":"Goldstein","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"2026061813271410400_B16","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s11325-011-0624-8","article-title":"Obstructive sleep apnea and kidney disease: is there any direct link?","volume":"16","author":"Mirrakhimov","year":"2012","journal-title":"Sleep Breath"},{"key":"2026061813271410400_B17","doi-asserted-by":"crossref","first-page":"e032580","DOI":"10.1161\/JAHA.123.032580","article-title":"Resting heart rate: a valuable marker for preventing kidney disease","volume":"12","author":"Abdin","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026061813271410400_B18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s11255-011-9997-7","article-title":"Risk factors for chronic kidney diseases may include periodontal diseases, as estimated by the correlations of plasma pentraxin-3 levels: a case-control study","volume":"44","author":"Pradeep","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"2026061813271410400_B19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.2017030253","article-title":"Particulate matter air pollution and the risk of incident CKD and progression to ESRD","volume":"29","author":"Bowe","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2026061813271410400_B20","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.2215\/CJN.13841215","article-title":"Climate change and the emergent epidemic of CKD from heat stress in rural communities: the case for heat stress nephropathy","volume":"11","author":"Glaser","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026061813271410400_B21","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026061813271410400_B22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026061813271410400_B23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"2026061813271410400_B24","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1001\/jama.290.23.3101","article-title":"Screening for proteinuria in US adults: a cost-effectiveness analysis","volume":"290","author":"Boulware","year":"2003","journal-title":"JAMA"},{"key":"2026061813271410400_B25","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/bmj.306.6894.1722","article-title":"Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes?","volume":"306","author":"Borch-Johnsen","year":"1993","journal-title":"BMJ"},{"key":"2026061813271410400_B26","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-131-9-199911020-00005","article-title":"The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors","volume":"131","author":"Golan","year":"1999","journal-title":"Ann Intern Med"},{"key":"2026061813271410400_B27","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/ndt\/gfn082","article-title":"A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA","volume":"23","author":"Palmer","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2026061813271410400_B28","doi-asserted-by":"crossref","first-page":"e067386","DOI":"10.1136\/bmjopen-2022-067386","article-title":"Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study","volume":"13","author":"Tangri","year":"2023","journal-title":"BMJ Open"},{"key":"2026061813271410400_B29","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.ekir.2020.07.029","article-title":"Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes","volume":"5","author":"Cabrera","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026061813271410400_B30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2017.04.019","article-title":"Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference","volume":"92","author":"Baigent","year":"2017","journal-title":"Kidney Int"},{"key":"2026061813271410400_B31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026061813271410400_B32","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026061813271410400_B33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.23876\/j.krcp.20.104","article-title":"Comparison of chronic kidney disease trial designs and analysis strategies","volume":"40","author":"Lawrence","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"2026061813271410400_B34","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.kint.2024.03.019","article-title":"Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect","volume":"105","author":"Yau","year":"2024","journal-title":"Kidney Int"},{"key":"2026061813271410400_B35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney Int"},{"key":"2026061813271410400_B36","doi-asserted-by":"crossref","first-page":"103465","DOI":"10.1016\/j.eclinm.2025.103465","article-title":"Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease","volume":"88","author":"Taylor","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026061813271410400_B37","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jamacardio.2021.5151","article-title":"Potential role and limitations of estimated glomerular filtration rate slope assessment in cardiovascular trials: a review","volume":"7","author":"Khan","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026061813271410400_B38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/ckj\/sfx083","article-title":"Patterns of progression of chronic kidney disease at later stages","volume":"11","author":"Caravaca-Font\u00e1n","year":"2018","journal-title":"Clin Kidney J"},{"key":"2026061813271410400_B39","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061813271410400_B40","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026061813271410400_B41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061813271410400_B42","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026061813271410400_B43","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061813271410400_B44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061813271410400_B45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/path.1711090304","article-title":"The parameters of the ageing kidney","volume":"109","author":"Darmady","year":"1973","journal-title":"J Pathol"},{"key":"2026061813271410400_B46","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/ki.2008.319","article-title":"The aging kidney","volume":"74","author":"Zhou","year":"2008","journal-title":"Kidney Int"},{"key":"2026061813271410400_B47","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1046\/j.1523-1755.2003.00207.x","article-title":"Determinants of glomerular hypofiltration in aging humans","volume":"64","author":"Hoang","year":"2003","journal-title":"Kidney Int"},{"key":"2026061813271410400_B48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/bs.vh.2024.02.007","article-title":"Advanced glycation end products and insulin resistance in diabetic nephropathy","volume":"125","author":"Parwani","year":"2024","journal-title":"Vitam Horm"},{"key":"2026061813271410400_B49","doi-asserted-by":"crossref","first-page":"108127","DOI":"10.1016\/j.jdiacomp.2022.108127","article-title":"Kidney hemodynamic profile and systemic vascular function in adults with type 2 diabetes: analysis of three clinical trials","volume":"36","author":"Hesp","year":"2022","journal-title":"J Diabetes Complications"},{"key":"2026061813271410400_B50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: an update","volume":"8","author":"Su","year":"2017","journal-title":"Front Immunol"},{"key":"2026061813271410400_B51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fcell.2020.00123","article-title":"Diverse role of TGF-\u03b2 in kidney disease","volume":"8","author":"Gu","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2026061813271410400_B52","doi-asserted-by":"crossref","first-page":"F1231","DOI":"10.1152\/ajprenal.00557.2012","article-title":"Tumor necrosis factor-\u03b1: regulation of renal function and blood pressure","volume":"304","author":"Ramseyer","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026061813271410400_B53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.yjmcc.2019.12.006","article-title":"Oxidative stress contributes to vascular calcification in patients with chronic kidney disease","volume":"138","author":"Huang","year":"2020","journal-title":"J Mol Cell Cardiol"},{"key":"2026061813271410400_B54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4614-0887-1_8","article-title":"FGF23 in chronic kidney disease","volume":"728","author":"Wahl","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"2026061813271410400_B55","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1523-1755.2001.030002587.x","article-title":"PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction","volume":"60","author":"Oda","year":"2001","journal-title":"Kidney Int"},{"key":"2026061813271410400_B56","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/biom10010154","article-title":"The association of matrix metalloproteinases with chronic kidney disease and peripheral vascular disease: a light at the end of the tunnel?","volume":"10","author":"Provenzano","year":"2020","journal-title":"Biomolecules"},{"key":"2026061813271410400_B57","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5527\/wjn.v2.i3.84","article-title":"Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases","volume":"2","author":"Zhao","year":"2013","journal-title":"World J Nephrol"},{"key":"2026061813271410400_B58","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026061813271410400_B59","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","article-title":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial","volume":"406","author":"Walsh","year":"2025","journal-title":"Lancet"},{"key":"2026061813271410400_B60","doi-asserted-by":"crossref","first-page":"e0265642","DOI":"10.1371\/journal.pone.0265642","article-title":"Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: a meta-analysis","volume":"17","author":"Hu","year":"2022","journal-title":"PLoS One"},{"key":"2026061813271410400_B61","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026061813271410400_B62","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/ajhp\/zxad192","article-title":"Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes","volume":"80","author":"Ashjian","year":"2023","journal-title":"Am J Health Syst Pharm"}],"container-title":["Diabetes Obesity and Cardiometabolic CARE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article-pdf\/1\/2\/278\/861058\/docm250017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article-pdf\/1\/2\/278\/861058\/docm250017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:27:23Z","timestamp":1781803643000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article\/1\/2\/278\/164607\/Estimated-Glomerular-Filtration-Rate-Slope-Chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":62,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,8]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/doc25-0017","relation":{},"ISSN":["3067-3518","3067-3534"],"issn-type":[{"value":"3067-3518","type":"print"},{"value":"3067-3534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}